{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:42:46Z","timestamp":1789843366676,"version":"4.0.1"},"reference-count":41,"publisher":"Walter de Gruyter GmbH","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jbcpp-2016-0057_s_999_w2aab2b8c45b1b7b1aab1c15b1Aa\">\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Several preclinical studies have shown that serotonergic 5-HT\n                      <jats:sub>3<\/jats:sub>\n                      receptor antagonists play an important role in the management of neuropsychiatric disorders, such as depression and anxiety. In the present study the compound \u201c6n\u201d (N-n-propyl-3-ethoxyquinoxaline-2-carboxamide), a novel 5-HT\n                      <jats:sub>3<\/jats:sub>\n                      receptor antagonist with an optimal log P (2.52) and\n                      <jats:italic>pA<\/jats:italic>\n                      <jats:sub>\n                        <jats:italic>2<\/jats:italic>\n                      <\/jats:sub>\n                      (7.6) value was screened for its neuro-pharmacological potential in chronic rodent models of depression and anxiety named traumatic brain injury (TBI).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2016-0057_s_998_w2aab2b8c45b1b7b1aab1c15b2Aa\">\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this model, a 1 cm midline scalp incision was made, and the muscles were retracted to expose the skull. A stainless steel disc (10 mm in diameter and 3 mm in depth) was placed centrally between the lambda and bregma regions. The injury was induced using the impact acceleration model of TBI. Specifically, a 400 g metal weight was dropped from a height of 1 m guided by a straight pipe, onto the metal disc placed over the rat\u2019s skull.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2016-0057_s_997_w2aab2b8c45b1b7b1aab1c15b3Aa\">\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The behavioral anomalies of the TBI rats were attenuated by the chronic treatment of compound 6n (1 and 2 mg\/kg, p.o.; 14 days) as observed by the modified open field test (ambulation, rearing, and fecal pellet), sucrose consumption test (% sucrose consumption), elevated plus maze [% open arm entries [OAE] and % time spent in open arm (TSOA)], and marble burying test (numbers). In addition, 6n also increased the levels of neurotransmitters (norepinephrine and serotonin) and brain derived neurotrophic factor (BDNF) in TBI rats.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2016-0057_s_996_w2aab2b8c45b1b7b1aab1c15b4Aa\">\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The result suggests that compound 6n exhibited antidepressant- and anxiolytic-like effects in rodent models of depression and anxiety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jbcpp-2016-0057","type":"journal-article","created":{"date-parts":[[2016,9,23]],"date-time":"2016-09-23T05:22:51Z","timestamp":1474608171000},"page":"93-100","source":"Crossref","is-referenced-by-count":12,"title":["Neuropharmacological and neurochemical evaluation of N\n                    <i>-<\/i>\n                    n\n                    <i>-<\/i>\n                    propyl-3-ethoxyquinoxaline-2-carboxamide (6n): a novel serotonergic 5-HT\n                    <sub>3<\/sub>\n                    receptor antagonist for co-morbid antidepressant- and anxiolytic-like potential using traumatic brain injury model in rats"],"prefix":"10.1515","volume":"28","author":[{"given":"Shvetank","family":"Bhatt","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Faculty of Pharmacy, M.S. Ramaiah University of Applied Sciences, Bangalore, Karnataka 560054, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhakrishnan","family":"Mahesh","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Birla Institute of Technology and Science (BITS), Pilani, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankur","family":"Jindal","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Birla Institute of Technology and Science (BITS), Pilani, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thangaraj","family":"Devadoss","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, School of Pharmacy, International Medical University (IMU), Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2016,9,23]]},"reference":[{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_001_w2aab2b8c45b1b7b1ab2b1b1Aa","unstructured":"Available at: http:\/\/www.adaa.org\/understanding-anxiety\/depression. Accessed 14 Feb 2016."},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_002_w2aab2b8c45b1b7b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Robert MA, Hirschfeld MD. The comorbidity of major depression and anxiety disorders: recognition and management in primary care. J Clin Psychiatry 2001;3:244\u201354.","DOI":"10.4088\/PCC.v03n0609"},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_003_w2aab2b8c45b1b7b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Duman RS, Voleti B. Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci 2012;35:47\u201356.","DOI":"10.1016\/j.tins.2011.11.004"},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_004_w2aab2b8c45b1b7b1ab2b1b4Aa","unstructured":"Available at: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK63740\/. Accessed 27 Feb 2016."},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_005_w2aab2b8c45b1b7b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Celada P, Puig M, Amarg\u00f3s-Bosch M, Adell A, Artigas F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 2004;29:252\u201365.","DOI":"10.1139\/jpn.0427"},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_006_w2aab2b8c45b1b7b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Pacher P, Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns. Curr Pharm Des 2004;10:2463\u201375.","DOI":"10.2174\/1381612043383872"},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_007_w2aab2b8c45b1b7b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Waring WS. Clinical use of antidepressant therapy and associated cardiovascular risk. Drug Healthc Patient Saf 2012;4:93\u2013101.","DOI":"10.2147\/DHPS.S28804"},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_008_w2aab2b8c45b1b7b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Hamet P, Tremblay J. Genetics and genomics of depression. Metabolism 2005;54:10\u201315.","DOI":"10.1016\/j.metabol.2005.01.006"},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_009_w2aab2b8c45b1b7b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Mahesh R, Bhatt S, Devadoss T, Jindal AK, Gautam BK, Pandey DK. Anti-depressant potential of 5-HT3 receptor antagonist, N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n). J Young Pharm 2012;4:235\u201344.","DOI":"10.4103\/0975-1483.104367"},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_010_w2aab2b8c45b1b7b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Bhatt S, Mahesh R, Devadoss T, Jindal AK. Antidepressant-like effect of novel 5-HT3 receptor antagonist N-n-butyl-3-ethoxyquinoxalin-2-carboxamide (6p): an approach using rodent behavioral antidepressant tests. Indian J Pharmacol 2013;45:348\u201353.","DOI":"10.4103\/0253-7613.115014"},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_011_w2aab2b8c45b1b7b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Betry C, Etievant A, Oosterhof C, Ebert B, Sanchez C, Haddjeri N. Role of 5-HT3 Receptors in the Antidepressant Response. Pharmaceuticals 2011;4:603\u201329.","DOI":"10.3390\/ph4040603"},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_012_w2aab2b8c45b1b7b1ab2b1c12Aa","unstructured":"Bhatt S, Mahesh R, Jindal A, Devadoss T. Anti-depressant-like activity of N-n-butyl-3-methoxyquinoxaline-2-carboxamide (6o) a 5-HT3 receptor antagonist. Indian J Exp Biol 2013;51: 435\u2013443."},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_013_w2aab2b8c45b1b7b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Gupta D, Mahesh R, Kurhe Y, Thangaraj D, Prabhakar V, Kanade P. Antidepressant-like effects of a novel 5-HT3 receptor antagonist 6z in acute and chronic murine models of depression. Acta Pharmacol Sin 2014;35:1493\u20131503.","DOI":"10.1038\/aps.2014.89"},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_014_w2aab2b8c45b1b7b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Rajkumar R, Mahesh R. The auspicious role of the 5-HT3 receptor indepression: a probable neuronal target. J Psychopharmacol 2010;24:455\u201369.","DOI":"10.1177\/0269881109348161"},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_015_w2aab2b8c45b1b7b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Vitalis S, Ansorge MS, Dayer AG. Serotonin homeostasis and serotonin receptors as actors of cortical construction: special attention to the 5-HT3A and 5-HT6 receptor subtypes. Front Cell Neurosci 2013;7:93.","DOI":"10.3389\/fncel.2013.00093"},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_016_w2aab2b8c45b1b7b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Sziray N, Leveleki C, Levay G, Harsing LG, Mikics E. Mechanism underlying the long term behavioural effects of traumatic experience in rats: the role of serotonin\/noradrenaline balance and NMDA receptors. Brain Res Bull 2007;71:376\u201385.","DOI":"10.1016\/j.brainresbull.2006.10.006"},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_017_w2aab2b8c45b1b7b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Foda MA, Marmarou A. A new model of diffuse brain injury in rats; Part II: morphological characterization. J Neurosurg 1994;80:301\u201313.","DOI":"10.3171\/jns.1994.80.2.0301"},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_018_w2aab2b8c45b1b7b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Heath DL, Vink R. Optimization of magnesium therapy following severe diffuse axonal brain injury in rats. J Pharm Exp Ther 1999;288:1311\u201316.","DOI":"10.1016\/S0022-3565(24)38087-5"},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_019_w2aab2b8c45b1b7b1ab2b1c19Aa","unstructured":"Mahesh R, Pandey DK, Katiyar S, Kukade G, Viyogi S, Rudra A. Effect of Anti-depressants on neuro-behavioural consequences following impact accelerated traumatic brain injury in rats. Indian J Exp Biol 2010;48:466\u201373."},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_020_w2aab2b8c45b1b7b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"Pandey DK, Yadav SK, Mahesh R, Ramamoorthy R. Depression-like and anxiety-like behavioural aftermaths of impact accelerated traumatic brain injury in rats: a model of comorbid depression and anxiety. Behav Brain Res 2009;205:436\u2013442.","DOI":"10.1016\/j.bbr.2009.07.027"},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_021_w2aab2b8c45b1b7b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Kelly JP, Wrynn AS, Leonard BE. The olfactory bulbectomized rat as a model of depression: an update. Pharmacol Ther 1997;74:299\u2013316.","DOI":"10.1016\/S0163-7258(97)00004-1"},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_022_w2aab2b8c45b1b7b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"Yamada K, Iida R, Miyamoto Y, Saito K, Sekikawa K, Seishima, M. Neurobehavioural alterations in mice with a targeted deletion of the tumor necrosis factor-\u03b1 gene: implications for emotional behaviour. J Neuroimmunol 2000;111:131\u201338.","DOI":"10.1016\/S0165-5728(00)00375-1"},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_023_w2aab2b8c45b1b7b1ab2b1c23Aa","doi-asserted-by":"crossref","unstructured":"Willner P, Muscat R, Papp M. Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci Biobehav Rev 1992;16:525\u201334.","DOI":"10.1016\/S0149-7634(05)80194-0"},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_024_w2aab2b8c45b1b7b1ab2b1c24Aa","doi-asserted-by":"crossref","unstructured":"Broekkamp CL, Rijk HW, Joly-gelo D, Lloyd KG. Major tranquilizer can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim induced grooming in mice. Eur J Pharmacol 1986;126:223\u201329.","DOI":"10.1016\/0014-2999(86)90051-8"},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_025_w2aab2b8c45b1b7b1ab2b1c25Aa","doi-asserted-by":"crossref","unstructured":"Glowinski J, Iversen LL. Regional studies of catecholamines in the rat brain. I. The disposition of [3H] nor-epinephrine, [3H] dopamine and [3H] dopa in various regions of the brain. J Neurochem 1966;13:655\u2013669.","DOI":"10.1111\/j.1471-4159.1966.tb09873.x"},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_026_w2aab2b8c45b1b7b1ab2b1c26Aa","doi-asserted-by":"crossref","unstructured":"Jorge R, Robinson RG. Mood disorders following traumatic brain injury. Neurorehabilitation 2002;17:311\u201324.","DOI":"10.3233\/NRE-2002-17405"},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_027_w2aab2b8c45b1b7b1ab2b1c27Aa","doi-asserted-by":"crossref","unstructured":"Kersel DA, Marsh NV, Havill JH, Sleigh JW. Psychosocial functioning during the year following severe traumatic brain injury. Brain Inj 2001;15:683\u201396.","DOI":"10.1080\/02699050010013662"},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_028_w2aab2b8c45b1b7b1ab2b1c28Aa","doi-asserted-by":"crossref","unstructured":"Ramamoorthy R, Radhakrishnan M, Borah M. Anti-depressant-like effects of serotonin type-3 antagonist, ondansetron: an investigation in behaviour-based rodent models. Behav Pharmacol 2008;19:29\u201340.","DOI":"10.1097\/FBP.0b013e3282f3cfd4"},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_029_w2aab2b8c45b1b7b1ab2b1c29Aa","unstructured":"Kulkarni SK. Open Field Test: its status in psychopharmacology. Indian J Pharmacol 1977;9:241\u201346."},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_030_w2aab2b8c45b1b7b1ab2b1c30Aa","doi-asserted-by":"crossref","unstructured":"Grahame K, Robyn L, Tate DL. Preventing suicide after traumatic brain injury: implications for general practice. Med J Aust 2007;187:229\u201332.","DOI":"10.5694\/j.1326-5377.2007.tb01206.x"},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_031_w2aab2b8c45b1b7b1ab2b1c31Aa","unstructured":"Berkowitz L. Aggression: its causes, consequences, and control. McGraw-Hill Series in Social Psychology. New York, NY: Mcgraw-Hill Book Company, 1993."},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_032_w2aab2b8c45b1b7b1ab2b1c32Aa","doi-asserted-by":"crossref","unstructured":"Hogg S. A review of the validity and variability of the elevated plus maze as an animal model of anxiety. Pharmacol Biochem Behav 1996;54:21\u201330.","DOI":"10.1016\/0091-3057(95)02126-4"},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_033_w2aab2b8c45b1b7b1ab2b1c33Aa","doi-asserted-by":"crossref","unstructured":"Wang D, Noda Y, Tsunekawa H, Masayuk Y, Zhoub SK, Nabeshima T. Behavioural and neuro-chemical features of olfactory bulbectomized rats resembling depression with co-morbid anxiety. Behav Brain Res 2007;178:262\u2013273.","DOI":"10.1016\/j.bbr.2007.01.003"},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_034_w2aab2b8c45b1b7b1ab2b1c34Aa","unstructured":"Available at: http:\/\/www.apa.org\/helpcenter\/symptoms-of-depression.aspx."},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_035_w2aab2b8c45b1b7b1ab2b1c35Aa","doi-asserted-by":"crossref","unstructured":"Jones NC, Cardamone L, Williams JP, Salzberg MR, Myers D, O\u2019Brien TJ. Experimental traumatic brain injury induces a pervasive hyperanxious phenotype in rats. J Neurotrauma 2008;2:1367\u201374.","DOI":"10.1089\/neu.2008.0641"},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_036_w2aab2b8c45b1b7b1ab2b1c36Aa","doi-asserted-by":"crossref","unstructured":"Koponen S, Taiminen T, Portin R. Axis I and II psychiatric disorders after traumatic brain injury: a 30-year follow-up study. Am J Psychiatry 2002;159:1315\u201321.","DOI":"10.1176\/appi.ajp.159.8.1315"},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_037_w2aab2b8c45b1b7b1ab2b1c37Aa","doi-asserted-by":"crossref","unstructured":"Jorge R, Robinson RG, Moser D. Major depression following traumatic brain injury. Arch Gen Psychiatry 2004;61:42\u201350.","DOI":"10.1001\/archpsyc.61.1.42"},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_038_w2aab2b8c45b1b7b1ab2b1c38Aa","doi-asserted-by":"crossref","unstructured":"Michael AJ, Brandum AD. Obsessive-compulsive disorder and head trauma: a rare association. J Anxiety Disord 1988;4:353\u201360.","DOI":"10.1016\/0887-6185(88)90030-8"},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_039_w2aab2b8c45b1b7b1ab2b1c39Aa","doi-asserted-by":"crossref","unstructured":"Ichimaru, Y, Egawa T, Sawa A. 5-HT 1A receptor subtype mediates the effect of fluvoxamine, a selective serotonin re-uptake inhibitor on marble burying behaviour in mice. Jpn J Pharmacol 1995;68:65\u201373.","DOI":"10.1254\/jjp.68.65"},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_040_w2aab2b8c45b1b7b1ab2b1c40Aa","doi-asserted-by":"crossref","unstructured":"Levine J, Cole DP, Chengappa KN, Gershon S. Anxiety disorders and major depression, together or apart. Depress Anxiety 2001;14:94\u2013104.","DOI":"10.1002\/da.1051"},{"key":"2025121209090675062_j_jbcpp-2016-0057_ref_041_w2aab2b8c45b1b7b1ab2b1c41Aa","doi-asserted-by":"crossref","unstructured":"Das M, Mohapatra S, Mohapatra SS. New perspectives on central and peripheral immune responses to acute traumatic brain injury. J Neuroinflammation 2012;9:236\u201347.","DOI":"10.1186\/1742-2094-9-236"}],"container-title":["Journal of Basic and Clinical Physiology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/jbcpp.2017.28.issue-2\/jbcpp-2016-0057\/jbcpp-2016-0057.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2016-0057\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2016-0057\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T11:41:31Z","timestamp":1765539691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2016-0057\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,23]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,9,24]]},"published-print":{"date-parts":[[2017,3,1]]}},"alternative-id":["10.1515\/jbcpp-2016-0057"],"URL":"https:\/\/doi.org\/10.1515\/jbcpp-2016-0057","relation":{},"ISSN":["2191-0286","0792-6855"],"issn-type":[{"value":"2191-0286","type":"electronic"},{"value":"0792-6855","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9,23]]}}}